Acute Lymphocytic Leukemia (ALL)

Introduction Acute lymphocytic leukemia ( ALL ) is an aggressive hematologic malignancy characterized by the clonal proliferation of immature lymphoid precursors, or lymphoblasts, in the bone marrow, blood, and other organs. While predominantly a pediatric cancer, with a peak incidence between ages 2 and 5, ALL also affects adults and presents unique challenges across age groups. For researchers ...
Acute lymphocytic leukaemia ( ALL ) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...
Acute Lymphoblastic Leukemia (ALL)

Acute lymphoblastic leukemia ( acute lymphocytic leukemia , ALL ) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. ALL is the most common type of cancer and leukemia in children in the United States. The image below shows pre-B-cell lymphoblastic leukemia /lymphoma (B-ALL).
Summary Acute lymphocytic leukaemia ( ALL ) is a haematological malignancy of the lymphoid progenitor cells. Enhanced genetic analyses have led to the identification of over 23 subtypes of B-cell and 17 subtypes of T-cell ALL .

Acute Lymphoblastic Leukemia Treatment
Acute lymphoblastic leukemia ( ALL ) treatment options include chemotherapy, radiation therapy, stem cell transplant, and/or targeted therapy. Get detailed information about newly diagnosed and recurrent ALL in this expert-reviewed summary.
Acute lymphocytic leukaemia ( ALL ) is a haematological malignancy of the lymphoid progenitor cells. Enhanced genetic analyses have led to the identification of over 23 subtypes of B-cell and 17 subtypes of T-cell ALL . In parallel, the development of highly sensitive measurable residual disease assays have refined disease monitoring and risk stratification. Breakthroughs in molecular ...

American Society of Hematology 2026 guidelines for frontline management ...
For adolescents and young adults (AYAs) with B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy) receiving frontline therapy, the American Society of Hematology (ASH) guideline panel recommends pediatric-inspired (asparaginase-containing) regimens (strong recommendation based on ...
Introduction Scientific progress in acute lymphoblastic leukemia ( ALL ) has been driven by the activities of national academic multicenter study groups in Europe and US in the past decades. The European national study groups have founded a collaboration within the European LeukemiaNet named European Working Group for Adult ALL .

Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia is the most common cancer in children, and represents approximately 75% of leukemias among children < 15 years of age. The risk declines slowly until the mid-20s and then begins to rise again slowly after age 50. ALL accounts for approximately 20% of adult acute leukemias .




Graphical Abstract This review covers diagnostic criteria and procedures for acute lymphoblastic leukaemia ( ALL ), the role of emerging technologies and biomarkers in refining diagnostic precision, and the potential impact of future innovations on the diagnosis and management of ALL .